Clinical News
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe
2 εβδομάδες ago
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe
The European Medicines Agency (EMA)’s safety committee (PRAC) has concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML). Zynteglo, a gene therapy…
Clinical Trials Update: The June 2021 Edition
3 εβδομάδες ago
Clinical Trials Update: The June 2021 Edition
TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
22 Ιουνίου, 2021
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…
TIF Is Actively Participating In The 26th EHA Annual Congress
15 Ιουνίου, 2021
TIF Is Actively Participating In The 26th EHA Annual Congress
TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
8 Ιουνίου, 2021
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
US STUDY: COVID-19 Does Not Pose A Threat To Blood And Transfusion Safety
3 Ιουνίου, 2021
US STUDY: COVID-19 Does Not Pose A Threat To Blood And Transfusion Safety
A new reassuring US study, published recently in the journal Transfusion, suggests that the risk of transmission of SARS-CoV2 through blood transfusion is highly unlikely. For the study, the investigators…
Chinese Sinovac COVID-19 Vaccine Approved By World Health Organization
2 Ιουνίου, 2021
Chinese Sinovac COVID-19 Vaccine Approved By World Health Organization
The World Health Organization (WHO) announced yesterday that it has approved a COVID-19 vaccine made by Sinovac Biotech (SVA.O) for emergency use listing, paving the way for a second Chinese shot…
Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
11 Απριλίου, 2021
Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…
Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System
1 Απριλίου, 2021
Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System
Hemanext Inc. announced today it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the…
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
20 Φεβρουαρίου, 2021
TIF’s Public Statement on Current Developments in Gene Therapy SCD Clinical Trials and Thalassaemia Gene Therapy Zynteglo
The Thalassaemia International Federation (TIF) has been informed through official communication by both the European Medicines Agency (EMA) and bluebird bio that the latter has placed Phase 1/2 and Phase…